<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201219049765N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-04</date_registration>
      <primary_sponsor>Rafsanjan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of consuming the liposomal form of pistachio kernel oil on multiple sclerosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of liposomal form of pistachio kernel oil and placebo on the level of some inflammatory and anti-inflammatory agents as well as their receptors in mononuclear cells in peripheral blood and change in the severity of clinical symptoms in women with multiple sclerosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>500</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57607</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method and description of each method: Simple randomization
Randomization unit: individual
Randomization tool: Excel software
How to build a random sequence: with RAND function in excel software
Allocation concealment: For allocation concealment, the method of Sequentially numbered, sealed, opaque envelopes (SNOSE) will be used, Blinding description: Participants, lead researcher, healthcare staff responsible for patient care, data collection and outcome assessors, data safety and monitoring committee, and drafters, They will keep blind. To simulate the intervention in 2 groups, similar vials in terms of volume, shape and appearance will be used.</study_design>
      <phase>3</phase>
      <hc_freetext>Multiple Sclerosis (MS).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: once a day, 5 ml, liposomal form of 10% pistachio kernel oil, orally, for 24 weeks. In this study, no special equipment is used and the explanations of this trial are given in printed form to the volunteers. Of course, entering this study does not require special training. The liposomal form of pistachio kernel oil is also prepared and approved by the Research Institute of Basic Medical Sciences of Rafsanjan University of Medical Sciences. Intervention 2: Control group: This group will be given the same as the placebo test group with the same intervention group program. In this study, no special equipment is used and the explanations of this trial are given in printed form to the volunteers. Of course, entering this study does not require special training. Pharmacopoeia is also prepared and approved by the Research Institute of Basic Medical Sciences of Rafsanjan University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on primary and secondary outcomes will be available to researchers

When:
Infinitely after the publication of the article

To whom:
Researchers and volunteers surveyed

Conditions:
For research work

Where to obtain:
Responsible of the project
Gholamhossein Hasanshahi
alijebal2011@gmail.com

How to obtain:
Formal request to the university and then refer to the project manager

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Gholam Hossein Hassan Shahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Address: Rafsanjan - Imam Ali Boulevard - Central Organization</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7717933777</zip>
        <telephone>+98 34 3428 0038</telephone>
        <email>alijebal2011@gmail.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Jebali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No2, Yaqut building, anbiya shomali Blvd, Yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915897671</zip>
        <telephone>+98 35 3833 0756</telephone>
        <email>alijebal2011@gmail.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 18 to 51 years 
Definite diagnosis of multiple sclerosis with a descriptive measure of disability rate between 1 to 3</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>51 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Taking corticosteroids during the study
Pregnancy and lactation
Active cardiovascular disease, liver disease, gastrointestinal disease, patients with Helicobacter pylori positive test, kidney disease, diabetes mellitus, respiratory disease and autoimmune diseases
Take multivitamin, mineral, antioxidant and pistachio kernel supplements during the 30 days before the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: once a day, 5 ml, liposomal form of 10% pistachio kernel oil, orally, for 24 weeks. In this study, no special equipment is used and the explanations of this trial are given in printed form to the volunteers. Of course, entering this study does not require special training. The liposomal form of pistachio kernel oil is also prepared and approved by the Research Institute of Basic Medical Sciences of Rafsanjan University of Medical Sciences.</i_keyword>
      <i_keyword>Control group: This group will be given the same as the placebo test group with the same intervention group program. In this study, no special equipment is used and the explanations of this trial are given in printed form to the volunteers. Of course, entering this study does not require special training. Pharmacopoeia is also prepared and approved by the Research Institute of Basic Medical Sciences of Rafsanjan University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Concentration of inflammatory and anti-inflammatory factors. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: With ELISA Kit.</prim_outcome>
      <prim_outcome>Relative expression of genes of receptors of inflammatory and anti-inflammatory agents. Timepoint: Intervention time (w0), 24 weeks after intervention (w24). Method of measurement: By Realtime PCR.</prim_outcome>
      <prim_outcome>The length and severity of the disease. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: According to the descriptive measurement of disability rate.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Allergies to pistachio compounds. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: Qualitative examination with patient self-declaration.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rafsanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-24</approval_date>
        <contact_name>Ethics Committee of Rafsanjan University of Medical Sciences</contact_name>
        <contact_address>Rafsanjan - Imam Ali Boulevard - Central University Organization - Postal Code: 7717933777 Rafsanjan Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
